News & Updates
Filter by Specialty:
Roflumilast shows treatment potential for seborrheic dermatitis
15 Sep 2022
byAudrey Abella
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
Roflumilast shows treatment potential for seborrheic dermatitis
15 Sep 2022Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022
byRoshini Claire Anthony
In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
14 Sep 2022MRNA booster shot durably bolsters defenses against severe COVID-19
14 Sep 2022
byJairia Dela Cruz
Boosting with an mRNA vaccine yields significant protection against severe COVID-19 and may keep people out of the hospital for up to 6 months, as shown in a Singapore study.